Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Cybin Inc (CYBN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/17/2025: CYBN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $85.61
1 Year Target Price $85.61
| 4 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -59.58% | Avg. Invested days 20 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 177.41M USD | Price to earnings Ratio - | 1Y Target Price 85.61 |
Price to earnings Ratio - | 1Y Target Price 85.61 | ||
Volume (30-day avg) 5 | Beta 1.13 | 52 Weeks Range 4.81 - 13.88 | Updated Date 07/17/2025 |
52 Weeks Range 4.81 - 13.88 | Updated Date 07/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.08 |
Earnings Date
Report Date 2025-07-01 | When - | Estimate -0.0248 | Actual -1.46 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -44.06% | Return on Equity (TTM) -57.49% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 58155094 | Price to Sales(TTM) 278.25 |
Enterprise Value 58155094 | Price to Sales(TTM) 278.25 | ||
Enterprise Value to Revenue 313.59 | Enterprise Value to EBITDA -3.79 | Shares Outstanding 23023600 | Shares Floating 17009015 |
Shares Outstanding 23023600 | Shares Floating 17009015 | ||
Percent Insiders - | Percent Institutions 48.73 |
Upturn AI SWOT
Cybin Inc
Company Overview
History and Background
Cybin Inc. is a biopharmaceutical company focused on developing psychedelic-based therapeutics. Founded in 2019, Cybin has rapidly advanced clinical trials and research into novel psychedelic molecules to address unmet mental health needs. It has grown through acquisitions and partnerships.
Core Business Areas
- Drug Discovery and Development: Focuses on discovering and developing novel psychedelic compounds and delivery systems for mental health disorders.
- Clinical Trials: Conducts clinical trials to evaluate the safety and efficacy of its psychedelic-based therapeutics.
Leadership and Structure
Doug Drysdale serves as the Chief Executive Officer. The company has a board of directors and various departments responsible for research, development, clinical operations, and corporate functions.
Top Products and Market Share
Key Offerings
- CYB003: A proprietary psilocybin analog being developed for the treatment of Major Depressive Disorder (MDD). Market share is currently not applicable as it is still under development. Competitors include companies working on psilocybin therapies such as COMPASS Pathways (CMPS) and Atai Life Sciences (ATAI).
- CYB004: A deuterated DMT molecule being developed for anxiety disorders. Market share is currently not applicable as it is still under development. Competitors include small companies working with DMT.
Market Dynamics
Industry Overview
The psychedelic therapeutics industry is emerging and rapidly growing, driven by increasing awareness of mental health challenges and the potential of psychedelic compounds to address these issues. Regulatory environments are evolving to accommodate research and potential approval of psychedelic therapies.
Positioning
Cybin is positioned as a leader in the development of novel psychedelic molecules and delivery systems. Its competitive advantage lies in its proprietary drug candidates and clinical trial programs.
Total Addressable Market (TAM)
The TAM for mental health treatments is substantial, estimated in the tens of billions of dollars annually. Cybin is positioned to capture a portion of this market with its innovative therapies. The TAM for depression alone is estimated at $15 billion by 2030.
Upturn SWOT Analysis
Strengths
- Proprietary drug candidates
- Strong intellectual property portfolio
- Experienced leadership team
- Focus on novel psychedelic molecules
- Advanced clinical trials
Weaknesses
- High cash burn rate
- Dependence on capital markets for funding
- Regulatory uncertainties
- Early-stage development risk
- Limited revenue generation
Opportunities
- Potential FDA approval of psychedelic therapies
- Partnerships with pharmaceutical companies
- Expansion into new indications
- Increasing acceptance of psychedelic treatments
- Growing market demand for mental health solutions
Threats
- Regulatory hurdles
- Competition from other psychedelic companies
- Clinical trial failures
- Negative public perception
- Intellectual property challenges
Competitors and Market Share
Key Competitors
- CMPS
- ATAI
- GHRS
Competitive Landscape
Cybin differentiates itself through its focus on deuterated molecules and novel delivery systems. Competitors like COMPASS Pathways are further along in clinical development with psilocybin therapies.
Growth Trajectory and Initiatives
Historical Growth: Growth is characterized by the expansion of its drug development pipeline and advancement of clinical trials.
Future Projections: Future growth depends on successful clinical trial outcomes and potential regulatory approvals. Analyst estimates suggest significant revenue potential if CYB003 or CYB004 are approved.
Recent Initiatives: Recent initiatives include the advancement of CYB003 into Phase 2 clinical trials and the initiation of preclinical studies for new psychedelic molecules.
Summary
Cybin is a speculative investment in the rapidly evolving psychedelic therapeutics industry. While the company possesses promising drug candidates and a strong intellectual property portfolio, it faces significant regulatory and financial hurdles. Successful clinical trial outcomes and potential FDA approval are crucial for future success, but its lack of revenue generation and dependence on capital markets poses risks.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Investor presentations
- Press releases
- Analyst reports
- Industry news sources
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. The psychedelic therapeutics industry is highly speculative, and investors should conduct their own due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cybin Inc
Exchange NYSE MKT | Headquaters Toronto, ON, Canada | ||
IPO Launch date 2019-09-13 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 50 | Website https://www.cybin.com |
Full time employees 50 | Website https://www.cybin.com | ||
Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. It also has a strategic partnership agreement with Segal Trials to support PARADIGM, a multinational pivotal phase 3 program evaluating CYB003 for the adjunctive treatment of major depressive disorder. The company is headquartered in Toronto, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.